220 related articles for article (PubMed ID: 36791206)
1. Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy.
Yang F; Zhang D; Jiang H; Ye J; Zhang L; Bagley SJ; Winkler J; Gong Y; Fan Y
Sci Transl Med; 2023 Feb; 15(683):eabq3558. PubMed ID: 36791206
[TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
Dong X; Ren J; Amoozgar Z; Lee S; Datta M; Roberge S; Duquette M; Fukumura D; Jain RK
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898734
[TBL] [Abstract][Full Text] [Related]
3. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
[TBL] [Abstract][Full Text] [Related]
4. IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity.
Alizadeh D; Wong RA; Gholamin S; Maker M; Aftabizadeh M; Yang X; Pecoraro JR; Jeppson JD; Wang D; Aguilar B; Starr R; Larmonier CB; Larmonier N; Chen MH; Wu X; Ribas A; Badie B; Forman SJ; Brown CE
Cancer Discov; 2021 Sep; 11(9):2248-2265. PubMed ID: 33837065
[TBL] [Abstract][Full Text] [Related]
5. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
[TBL] [Abstract][Full Text] [Related]
6. An immunosuppressive vascular niche drives macrophage polarization and immunotherapy resistance in glioblastoma.
Yang F; Akhtar MN; Zhang D; El-Mayta R; Shin J; Dorsey JF; Zhang L; Xu X; Guo W; Bagley SJ; Fuchs SY; Koumenis C; Lathia JD; Mitchell MJ; Gong Y; Fan Y
Sci Adv; 2024 Mar; 10(9):eadj4678. PubMed ID: 38416830
[TBL] [Abstract][Full Text] [Related]
7. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
9. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40.
Yang F; He Z; Duan H; Zhang D; Li J; Yang H; Dorsey JF; Zou W; Nabavizadeh SA; Bagley SJ; Abdullah K; Brem S; Zhang L; Xu X; Byrne KT; Vonderheide RH; Gong Y; Fan Y
Nat Commun; 2021 Jun; 12(1):3424. PubMed ID: 34103524
[TBL] [Abstract][Full Text] [Related]
10. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
Song Y; Liu Q; Zuo T; Wei G; Jiao S
Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131
[TBL] [Abstract][Full Text] [Related]
11. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma.
Agliardi G; Liuzzi AR; Hotblack A; De Feo D; Núñez N; Stowe CL; Friebel E; Nannini F; Rindlisbacher L; Roberts TA; Ramasawmy R; Williams IP; Siow BM; Lythgoe MF; Kalber TL; Quezada SA; Pule MA; Tugues S; Straathof K; Becher B
Nat Commun; 2021 Jan; 12(1):444. PubMed ID: 33469002
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
[TBL] [Abstract][Full Text] [Related]
16. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.
Otvos B; Silver DJ; Mulkearns-Hubert EE; Alvarado AG; Turaga SM; Sorensen MD; Rayman P; Flavahan WA; Hale JS; Stoltz K; Sinyuk M; Wu Q; Jarrar A; Kim SH; Fox PL; Nakano I; Rich JN; Ransohoff RM; Finke J; Kristensen BW; Vogelbaum MA; Lathia JD
Stem Cells; 2016 Aug; 34(8):2026-39. PubMed ID: 27145382
[TBL] [Abstract][Full Text] [Related]
17. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy.
Zhang D; Li AM; Hu G; Huang M; Yang F; Zhang L; Wellen KE; Xu X; Conn CS; Zou W; Kahn M; Rhoades SD; Weljie AM; Fuchs SY; Amankulor N; Yoshor D; Ye J; Koumenis C; Gong Y; Fan Y
Cell Metab; 2023 Mar; 35(3):517-534.e8. PubMed ID: 36804058
[TBL] [Abstract][Full Text] [Related]
18. Natural Killer Cell-Based Immunotherapy against Glioblastoma.
Morimoto T; Nakazawa T; Maeoka R; Nakagawa I; Tsujimura T; Matsuda R
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768432
[TBL] [Abstract][Full Text] [Related]
19. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
20. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
